March 17, 2026 | Announcements
How GRAS reform, NDI guidance, and enforcement priorities are reshaping regulatory strategy.
The FDA’s Human Foods Program (HFP) 2026 agenda represents more than a routine update. Instead, it signals a structural shift in how ingredients, supplements, and food products are evaluated, documented, and enforced.
While many elements remain in the proposal or development stage, the direction is clear: greater transparency, stronger substantiation, and more formalized oversight.
For supplement and functional food brands, this is an inflection point. Companies that proactively align with these priorities will reduce risk, accelerate product development, and strengthen credibility with retailers and consumers.
Since the original January announcement, FDA has taken a meaningful next step.
In March 2026, the agency announced a public meeting on “Exploring the Scope of Dietary Supplement Ingredients” (March 27, 2026). FDA also released an agenda and supporting memo, with public comments open through April 27.
This is the first concrete signal that FDA is:
Key Takeaway: FDA has not yet finalized new rules, but it is actively building the regulatory foundation for future changes.
One of the most consequential developments is FDA’s plan to publish a proposed rule requiring GRAS notices for all new substances marketed under a GRAS determination.
Currently, companies can self-determine GRAS status without notifying FDA. If this rule is implemented, that flexibility could narrow significantly.
Ingredient onboarding may become slower and more resource-intensive
FDA visibility into new ingredients would increase
Informal or weak GRAS determinations could face greater scrutiny
Audit all GRAS-based ingredients for scientific and expert-review support
Identify new vs. legacy ingredients
Ensure safety dossiers include exposure, toxicology, and intended-use data
Source: FDA, 2026 Priority Deliverables
FDA continues to prioritize chemical safety and contaminant reduction, including:
This reflects a broader shift: compliance is no longer just about legality. It’s about demonstrating control and safety over time.
Source: FDA, 2026 Priority Deliverables
The FDA is increasing attention on consumer-facing transparency, particularly around:
Even if not immediately required, these areas are becoming competitive differentiators. Brands that proactively disclose will likely gain trust—and reduce future compliance risk.
Source: FDA, 2026 Priority Deliverables
FDA plans to release final guidance on New Dietary Ingredient (NDI) submissions in 2026, with an emphasis on improving review efficiency and consistency.
The agency also aims to better meet the statutory 75-day review timeline, suggesting a push toward more standardized and complete submissions.
Source: FDA, 2026 Priority Deliverables
FDA explicitly states it will explore modernized regulatory approaches for dietary supplements, noting that the market has evolved significantly since DSHEA (1994).
However, the agency has not yet defined the exact policy framework.
Industry coverage highlights both opportunity and concern—depending on how FDA balances innovation vs. compliance burden.
As regulatory expectations evolve, formulation strategy needs to become more deliberate. It is no longer enough to select ingredients based only on trend appeal or label marketing potential.
Instead, brands should evaluate whether each ingredient, excipient, and delivery format can stand up to increasing scrutiny around safety, identity, substantiation, and finished-product quality.
Prioritize ingredients with strong regulatory support, clear identity specifications, and well-documented safety data. Novel ingredients may still offer value, but they should be evaluated more carefully for GRAS, NDI, or other regulatory implications before development moves too far forward.
Build full supply chain visibility into the formulation process from the start. That includes knowing where ingredients come from, how they are processed, and whether supplier documentation is complete, current, and consistent with product positioning.
Consider contaminant risk early, especially for botanicals, minerals, marine-sourced ingredients, and products intended for sensitive populations. Heavy metals, PFAS, microplastics, solvents, and other contaminants are becoming a more important part of the quality conversation.
Evaluate stability early to confirm the product maintains potency, sensory quality, and shelf life throughout its intended lifecycle. Factors such as moisture, oxidation, ingredient interactions, and packaging selection can all influence whether a formulation performs consistently from production through consumer use.
Make sure formulation decisions support the claims and disclosures the brand intends to use. If an ingredient’s regulatory status, dosage, or function creates ambiguity, that issue should be resolved before label copy and marketing language are finalized.
Choose ingredients and formats that are not only compliant today, but also likely to remain defensible as FDA guidance evolves. A formulation that minimizes gray-area ingredients can reduce the risk of relabeling, reformulation, or interrupted commercialization later.
Confirm that supplier files include more than a marketing spec sheet. Brands should have access to meaningful documentation such as identity data, manufacturing details, certificates of analysis, and supporting safety information where appropriate.
Evaluate whether the delivery format supports both compliance and product stability. Gummies, powders, capsules, and functional food-style formats may each introduce different considerations related to ingredient compatibility, dosage accuracy, moisture, flavor systems, and shelf life.
The Human Foods Program is not just a regulatory update. It’s a directional signal for the industry.
FDA is moving toward:
As a result, regulatory strategy is becoming a competitive advantage, not just a compliance function.
Brands that wait for final rules will be reacting. Brands that act now will be positioned to lead.
Now is the time to:
Intermountain Nutrition partners with supplement brands to develop compliant, forward-looking formulations backed by rigorous quality and testing standards.
Are these FDA changes already in effect?
No. Most elements of the Human Foods Program 2026 agenda are planned actions, not finalized regulations. The FDA has indicated it will publish proposed rules, guidance documents, and strategic frameworks throughout 2026.
This means brands are not yet legally required to comply with changes like mandatory GRAS notification. However, companies should treat these updates as strong indicators of future expectations.
Proactively aligning with these priorities now can reduce regulatory risk, prevent costly reformulations, and improve speed to market once rules are finalized. In practice, forward-looking compliance is becoming a key differentiator.
How will GRAS reform impact product development timelines?
If FDA finalizes a requirement for mandatory GRAS notifications, product development timelines could extend significantly. Currently, companies can self-affirm GRAS status without notifying FDA, which allows for faster ingredient commercialization.
A mandatory notification system would introduce additional review steps, documentation requirements, and potential delays. Brands may need to build more robust safety dossiers and plan for regulatory review windows before launch. As a result, early-stage formulation decisions and supplier selection will become more critical to maintaining speed and flexibility.
What is the biggest risk area for supplement brands right now?
The biggest risk is misalignment between claims, ingredients, and substantiation. The FDA is signaling increased enforcement against violative products, particularly those making disease claims or using inadequately supported ingredients.
Brands with weak documentation, unclear ingredient identity, or aggressive marketing language are most vulnerable. Additionally, products sold through e-commerce channels face heightened scrutiny due to visibility and accessibility. Conducting a full audit of claims and ingredient files is one of the most effective ways to reduce exposure.
Will NDI guidance make innovation harder?
NDI guidance could make innovation more structured, but not necessarily harder. FDA’s goal appears to be improving both clarity and efficiency in the review process. While this may raise expectations for safety and identity data, it could also reduce uncertainty for well-prepared submissions.
Brands that invest in strong scientific substantiation and supplier transparency may actually benefit from a more predictable pathway. However, companies relying on ambiguous regulatory interpretations or incomplete documentation may face increased barriers.
How should brands prepare for increased FDA enforcement?
Preparation should focus on documentation, alignment, and consistency. Brands should ensure that all product claims are substantiated and compliant across every channel, including labels, websites, and retailer listings.
Ingredient files should be complete, with clear identity, safety, and manufacturing documentation. Additionally, companies should strengthen quality systems, including contaminant testing and supplier verification.
Establishing cross-functional alignment between regulatory, marketing, and product development teams is essential to prevent compliance gaps and ensure readiness for increased scrutiny.
U.S. Food and Drug Administration. (2026). Human Foods Program 2026 Priority Deliverables.
U.S. Food and Drug Administration. (n.d.). New Dietary Ingredient (NDI) Notification Process.
U.S. Food and Drug Administration. (2024). FDA issues final guidance on new dietary ingredient notification procedures and timeframes.
U.S. Food and Drug Administration. (n.d.). Generally Recognized as Safe (GRAS).
U.S. Food and Drug Administration. (n.d.). GRAS Notice Inventory.
U.S. Food and Drug Administration. (n.d.). How U.S. FDA’s GRAS notification program works.
U.S. Food and Drug Administration. (n.d.). Guidance for Industry: Food Labeling Guide.
U.S. Food and Drug Administration. (n.d.). New Dietary Ingredient (NDI) Notification Electronic Submissions.
NutraIngredients. (2026). FDA releases HFP priorities: All eyes on modernizing dietary supplement oversight, GRAS, NDIs.
https://intermountainnutrition.com/wp-content/uploads/2026/04/sustainable-ingredient-sourcing-16.jpg 1200 1200 Larisa Graham https://intermountainnutrition.com/wp-content/uploads/2026/01/IMN-gradient-logo-NEW.png Larisa Graham2026-04-09 10:30:002026-04-06 03:57:04Sustainable Ingredient Sourcing https://intermountainnutrition.com/wp-content/uploads/2026/04/electrolytes-for-hydration-02.jpg 1200 1200 Larisa Graham https://intermountainnutrition.com/wp-content/uploads/2026/01/IMN-gradient-logo-NEW.png Larisa Graham2026-04-07 10:30:002026-04-06 03:19:13Advancements in Electrolyte Absorption https://intermountainnutrition.com/wp-content/uploads/2026/04/electrolytes-for-hydration-05.jpg 1200 1200 Larisa Graham https://intermountainnutrition.com/wp-content/uploads/2026/01/IMN-gradient-logo-NEW.png Larisa Graham2026-04-03 09:00:002026-04-06 01:29:10Flavor Challenges in Hydration Supplements
Peptide-Based Recovery Supplements